Our current findings underscore the potential of using myeloid cell-targeted STAT3 inhibition to overcome resistance of genitourinary cancers, such as kidney and bladder cancers, to immunotherapy and trigger CD8 T-cell-mediated antitumor immune responses. Here, CD8A is linked to urinary bladder cancer.